- Home
- CLSK vs AXSM Comparison
CLSK vs AXSM Comparison
Compare CLSK & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- AXSM
- Stock Information
- Founded
- CLSK 1987
- AXSM 2012
- Country
- CLSK United States
- AXSM United States
- Employees
- CLSK N/A
- AXSM N/A
- Industry
- CLSK Finance: Consumer Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- AXSM Health Care
- Exchange
- CLSK Nasdaq
- AXSM Nasdaq
- Market Cap
- CLSK 5.7B
- AXSM 5.9B
- IPO Year
- CLSK N/A
- AXSM 2015
- Fundamental
- Price
- CLSK $10.99
- AXSM $139.80
- Analyst Decision
- CLSK Strong Buy
- AXSM Strong Buy
- Analyst Count
- CLSK 11
- AXSM 20
- Target Price
- CLSK $24.23
- AXSM $176.00
- AVG Volume (30 Days)
- CLSK 31.6M
- AXSM 545.5K
- Earning Date
- CLSK 12-01-2025
- AXSM 11-03-2025
- Dividend Yield
- CLSK N/A
- AXSM N/A
- EPS Growth
- CLSK N/A
- AXSM N/A
- EPS
- CLSK 0.98
- AXSM N/A
- Revenue
- CLSK $631,937,000.00
- AXSM $561,263,000.00
- Revenue This Year
- CLSK $109.84
- AXSM $63.66
- Revenue Next Year
- CLSK $39.96
- AXSM $54.46
- P/E Ratio
- CLSK $11.17
- AXSM N/A
- Revenue Growth
- CLSK 84.66
- AXSM 65.83
- 52 Week Low
- CLSK $6.45
- AXSM $75.56
- 52 Week High
- CLSK $23.61
- AXSM $144.15
- Technical
- Relative Strength Index (RSI)
- CLSK 28.63
- AXSM 64.97
- Support Level
- CLSK $14.06
- AXSM $123.50
- Resistance Level
- CLSK $16.52
- AXSM $144.15
- Average True Range (ATR)
- CLSK 1.44
- AXSM 5.54
- MACD
- CLSK -0.87
- AXSM -0.03
- Stochastic Oscillator
- CLSK 1.01
- AXSM 78.50
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.